CATALOGO DEI PRODOTTI DELLA RICERCA
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishChronic obstructive pulmonary disease (COPD) is a common diseasecharacterized by airflow obstruction and lung hyperinflation leading to dyspnea and exercisecapacity limitation.Objectives: The present study was designed to evaluate whether an extra-fine combinationof beclomethasone and formoterol (BDP/F) was effective in reducing air trapping in COPDpatients with hyperinflation. Fluticasone salmeterol (FP/S) combination treatment was theactive control.Methods: COPD patients with forced expiratory volume in one second ,65% andplethysmographic functional residual capacity $120% of predicted were randomized to a doubleblind,double-dummy, 12-week, parallel group, treatment with either BDP/F 400/24 μg/dayor FP/S 500/100 μg/day. Lung volumes were measured with full body plethysmography, anddyspnea was measured with transition dyspnea index.
| Titolo: | Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients |
| Autori: | |
| Data di pubblicazione: | 2011 |
| Rivista: | |
| Abstract: | Chronic obstructive pulmonary disease (COPD) is a common diseasecharacterized by airflow obstruction and lung hyperinflation leading to dyspnea and exercisecapacity limitation.Objectives: The present study was designed to evaluate whether an extra-fine combinationof beclomethasone and formoterol (BDP/F) was effective in reducing air trapping in COPDpatients with hyperinflation. Fluticasone salmeterol (FP/S) combination treatment was theactive control.Methods: COPD patients with forced expiratory volume in one second ,65% andplethysmographic functional residual capacity $120% of predicted were randomized to a doubleblind,double-dummy, 12-week, parallel group, treatment with either BDP/F 400/24 μg/dayor FP/S 500/100 μg/day. Lung volumes were measured with full body plethysmography, anddyspnea was measured with transition dyspnea index. |
| Handle: | http://hdl.handle.net/11562/1030137 |
| Appare nelle tipologie: | 01.01 Articolo in Rivista |
File in questo prodotto:
http://hdl.handle.net/11562/1030137
Copyright © 2021